Phase II trial of docetaxel in advanced or metastatic endometrial cancer

A Japanese Cooperative Study

N. Katsumata, K. Noda, S. Nozawa, R. Kitagawa, R. Nishimura, S. Yamaguchi, Daisuke Aoki, N. Susumu, H. Kuramoto, T. Jobo, K. Ueki, M. Ueki, I. Kohno, K. Fujiwara, Y. Sohda, F. Eguchi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status ≤2 entered the study. Docetaxel 70 mg m-2 was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39-74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1-50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3-4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.

Original languageEnglish
Pages (from-to)999-1004
Number of pages6
JournalBritish Journal of Cancer
Volume93
Issue number9
DOIs
Publication statusPublished - 2005 Oct 31

Fingerprint

docetaxel
Endometrial Neoplasms
Neutropenia
Drug Therapy
Febrile Neutropenia

Keywords

  • Docetaxel
  • Endometrial cancer
  • Phase II

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Katsumata, N., Noda, K., Nozawa, S., Kitagawa, R., Nishimura, R., Yamaguchi, S., ... Eguchi, F. (2005). Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study. British Journal of Cancer, 93(9), 999-1004. https://doi.org/10.1038/sj.bjc.6602817

Phase II trial of docetaxel in advanced or metastatic endometrial cancer : A Japanese Cooperative Study. / Katsumata, N.; Noda, K.; Nozawa, S.; Kitagawa, R.; Nishimura, R.; Yamaguchi, S.; Aoki, Daisuke; Susumu, N.; Kuramoto, H.; Jobo, T.; Ueki, K.; Ueki, M.; Kohno, I.; Fujiwara, K.; Sohda, Y.; Eguchi, F.

In: British Journal of Cancer, Vol. 93, No. 9, 31.10.2005, p. 999-1004.

Research output: Contribution to journalArticle

Katsumata, N, Noda, K, Nozawa, S, Kitagawa, R, Nishimura, R, Yamaguchi, S, Aoki, D, Susumu, N, Kuramoto, H, Jobo, T, Ueki, K, Ueki, M, Kohno, I, Fujiwara, K, Sohda, Y & Eguchi, F 2005, 'Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study', British Journal of Cancer, vol. 93, no. 9, pp. 999-1004. https://doi.org/10.1038/sj.bjc.6602817
Katsumata, N. ; Noda, K. ; Nozawa, S. ; Kitagawa, R. ; Nishimura, R. ; Yamaguchi, S. ; Aoki, Daisuke ; Susumu, N. ; Kuramoto, H. ; Jobo, T. ; Ueki, K. ; Ueki, M. ; Kohno, I. ; Fujiwara, K. ; Sohda, Y. ; Eguchi, F. / Phase II trial of docetaxel in advanced or metastatic endometrial cancer : A Japanese Cooperative Study. In: British Journal of Cancer. 2005 ; Vol. 93, No. 9. pp. 999-1004.
@article{52e0a2ade851419abb72d589a28330e6,
title = "Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study",
abstract = "The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-na{\"i}ve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status ≤2 entered the study. Docetaxel 70 mg m-2 was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39-74 years) who entered the study, 14 patients (42{\%}) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31{\%} (95{\%} confidence interval, 16.1-50.0{\%}); complete response and partial response (PR) were 3 and 28{\%}, respectively. Of 13 pretreated patients, three (23{\%}) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3-4 neutropenia, occurring in 94{\%} of the patients, although febrile neutropenia arose in 9{\%} of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.",
keywords = "Docetaxel, Endometrial cancer, Phase II",
author = "N. Katsumata and K. Noda and S. Nozawa and R. Kitagawa and R. Nishimura and S. Yamaguchi and Daisuke Aoki and N. Susumu and H. Kuramoto and T. Jobo and K. Ueki and M. Ueki and I. Kohno and K. Fujiwara and Y. Sohda and F. Eguchi",
year = "2005",
month = "10",
day = "31",
doi = "10.1038/sj.bjc.6602817",
language = "English",
volume = "93",
pages = "999--1004",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Phase II trial of docetaxel in advanced or metastatic endometrial cancer

T2 - A Japanese Cooperative Study

AU - Katsumata, N.

AU - Noda, K.

AU - Nozawa, S.

AU - Kitagawa, R.

AU - Nishimura, R.

AU - Yamaguchi, S.

AU - Aoki, Daisuke

AU - Susumu, N.

AU - Kuramoto, H.

AU - Jobo, T.

AU - Ueki, K.

AU - Ueki, M.

AU - Kohno, I.

AU - Fujiwara, K.

AU - Sohda, Y.

AU - Eguchi, F.

PY - 2005/10/31

Y1 - 2005/10/31

N2 - The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status ≤2 entered the study. Docetaxel 70 mg m-2 was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39-74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1-50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3-4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.

AB - The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status ≤2 entered the study. Docetaxel 70 mg m-2 was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39-74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1-50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3-4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.

KW - Docetaxel

KW - Endometrial cancer

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=27644465342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644465342&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602817

DO - 10.1038/sj.bjc.6602817

M3 - Article

VL - 93

SP - 999

EP - 1004

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -